

ALCHEMVER

Alchemver is a Pune-based life sciences consultancy founded in 2021, specializing in pharmaceutical forecasting, market access, and HEOR. With a "Human Intelligence-First" approach, it blends AI/ML, GenAI, and cloud tech with expert insights to deliver impactful. Serving clients across the US, Europe, and Asia, Alchemver helps biopharma companies make smarter, data-driven decisions in drug development, commercialization, and market strategy.

Project Assigned


Market Assessment & Market Access Of Endometriosis – US Market

The project focused on analyzing the endometriosis treatment landscape in the U.S., including disease burden, pricing, access challenges, and pipeline opportunities. I worked on market sizing, treatment trends, and patient journey mapping. The insights contributed to strategic recommendations for better access and commercial success.

Market Size & Forecast


- ✓ 2024 Market Size: USD 1,761.1 Million
- ✓ 2030 Projected Market Size: USD 3,520.0 Million
- ✓ CAGR (2025-2030): 12.3%
- ✓ North America: Largest market in 2024

Endometriosis Treatment Market Size, by Region, 2018 – 2030




- Affects 10–15% of women of reproductive age
- Common in women aged 25–45; also seen in teens and postmenopausal women
- 35–50% of women with pelvic pain/infertility may have it
- U.S. prevalence: ~6.5 million women
- Diagnosis delay: 7–10 years
- Ethnic rates: Asian (~15%), Caucasian (~12%), Black (~7%)
- Detected in 0.1–53% during surgery

Estimated Prevalence of Endometriosis by Ethnicity (U.S.)




MARKET SEGMENTATION


BY TREATMENT TYPE




BY ROUTE OF ADMINISTRATION



BY DISTRIBUTION TYPE



BY REGION TYPE



Market Access & Reimbursement (US Focus)

COVERAGE LANDSCAPE

Private Insurance: Covers FDA-approved options like Orilissa (elagolix), Oriahnn, and Myfembree, typically with prior authorization and step therapy requirements (Aetna, 2024).

Public Insurance: Medicare and Medicaid reimburse some therapies, but with significant restrictions and clinical criteria (Orilissa site, PubMed).

ACCESS BARRIERS

High cost of branded medications (~\$845–\$900/month)

Limited awareness and education among providers about newer therapies

Diagnostic procedures (e.g., laparoscopy) often not fully covered

PHARMA STRATEGIES

Copay support programs reducing costs for commercially insured patients (e.g., Myfembree copay card to as low as \$5/month; excludes Medicare/Medicaid)

Continuing Medical Education (CME) and provider outreach programs

Real-World Evidence (RWE) to support inclusion on formularies and demonstrate cost-effectiveness (Becaris Publishing)

Drug Cost Comparison Table

Drug Name	Manufacturer	Mechanism/Class	Monthly List Price
Orilissa (elagolix)	AbbVie	Oral GnRH Antagonist	~\$845–\$970
Myfembree	Myovant	Relugolix + E2 + NETA	~\$1,400 (retail) / ~\$900 (insured)



Key Pricing & Access Challenges

- OUT OF POCKET BURDEN:**
 - Uninsured or underinsured patients pay full retail price
 - Copay cards not available for Medicare/Medicaid patients
- ADHERENCE DROP OFF:**
 - High costs lead to poor long-term adherence
 - Some patients stop treatment within 3–6 months
- ACCESS BARRIERS:**
 - Medicaid & many commercial plans require prior authorization
 - Limited formulary inclusion in some states

Market Trends & Future Outlook

- 2023–2027:** RWE studies (e.g., Elagolix cost-effectiveness) gain traction. Insurance plans slowly expand coverage.
- 2028 onward:** Price negotiations via pharmacy benefit managers (PBMs). Shift toward value-based access models.
- 2029:** Patient registry for Orilissa → generic entry. Formulary competition and price pressure rise. Possible Medicaid expansion of access.

Theoretical Vs Practical Understanding

Practical Exposure

- Applied knowledge on real industry projects generate multiple task scenario at Alchemver.
- Mapping access barriers
- Estimating cost offsets from avoiding crisis and hospitalizations
- Improved decision-making, communication, and corporate readiness by tackling real-world tasks.

Theoretical Exposure

- Learned core market concepts, data analysis, and pharma fundamentals.
- Market Access and analysis
- Health economics and outcomes research (HEOR).
- Focused on concepts and frameworks relevant to healthcare consulting.

Learning Outcomes

- Pharmaceutical Forecasting Techniques
- Health Economics and Outcomes Research (HEOR)
- Competitive Analysis
- Understanding AI–Human Consulting at Alchemver
- Enhanced Communication Skills
- Enhanced Presentation Skills

Challenges faced During Internship

- Navigating Complex Rare Disease Data
- Understanding US Reimbursement Ecosystem
- Adapting to Real-world Consulting Flow
- Handled incomplete data with precision.
- Maintained work-life balance under tight deadlines.

Suggestions

- Schedule regular one-on-one meetings
- Set clear project goals and expectations
- Encourage open dialogue and feedback
- Use collaborative tools and platforms
- Document discussions and action points
- Provide timely support and guidance
- Review progress together regularly